| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000019359 |
| Receipt No. | R000022387 |
| Scientific Title | Investigation of the bio-markers in infants predicting the onset of childhood asthma |
| Date of disclosure of the study information | 2015/10/15 |
| Last modified on | 2022/10/26 (Ver. 8) |
| Basic information | ||
| Public title | Investigation of the bio-markers in infants predicting the onset of childhood asthma | |
| Acronym | Investigation of the bio-markers predicting the onset of childhood asthma | |
| Scientific Title | Investigation of the bio-markers in infants predicting the onset of childhood asthma | |
| Scientific Title:Acronym | Investigation of the bio-markers predicting the onset of childhood asthma | |
| Region |
|
|
| Condition | ||
| Condition | Childhood asthma | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Investigation of the bio-markers predicting the onset of childhood asthma |
| Basic objectives2 | Others |
| Basic objectives -Others | Investigation of the bio-markers predicting the onset of childhood asthma |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Others |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Onset of childhood asthma |
| Key secondary outcomes | persistent wheeze at 5 or 6 years of age |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients consulted the National Center for Child Health and Development or Tokai University Hospital | |||
| Key exclusion criteria | (1)Patients with repeated nose bleeding by pituita suction
(2)Patients receiving systemic corticosteroid treatment (3)Patients with other difficulties judged by the attending doctor |
|||
| Target sample size | 100 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | National Center for Child Health and Development | ||||||
| Division name | Department of allergy and clinical immunology | ||||||
| Zip code | 157-8535 | ||||||
| Address | 2-10-1 Okura Setagaya, Tokyo 157-8535 | ||||||
| TEL | 03-5494-7120(4970) | ||||||
| sugie-m@ncchd.go.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | National Center for Child Health and Development | ||||||
| Division name | Department of allergy and clinical immunology | ||||||
| Zip code | 157-8535 | ||||||
| Address | 2-10-1 Okura Setagaya, Tokyo 157-8535 | ||||||
| TEL | 03-5494-7120(4970) | ||||||
| Homepage URL | |||||||
| sugie-m@ncchd.go.jp | |||||||
| Sponsor | |
| Institute | National Center for Child Health and Development |
| Institute | |
| Department | |
| Funding Source | |
| Organization | National Center for Child Health and Development |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | Department of Pediatrics, Tokai University
Division of allergy, Department of medical subspecialties, National Center for Child Health and Development |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | National Center for Child Health and Development |
| Address | 2-10-1 Okura Setagaya, Tokyo 157-8535 |
| Tel | 03-3416-0181 |
| rinri@ncchd.go.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 国立研究開発法人 国立成育医療研究センター (東京都)
(National Center for Child Health and Development) 東海大学医学部専門診療学系小児科学 (神奈川県) (Department of Pediatrics, Tokai University) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | Study design: prospective cohort study
Subject recruiting method: October 2015-Oct 2016 Patients consulted the National Center for Child Health and Development or Tokai University Hospital except for key exclusion criteria who fulfill inclusion criteria (1)Age (at the blood sampling) (2)Sex (3)Family history: Allergic disease (4)Medical history: (asthma, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, food allergy ) (5)Serum specific IgE: within a year before/after the blood sampling (Dermatophagoides pteronyssinus, Japanease cedar, dog dander, cat danger, Alternaria ) (6)Total serum IgE (7)Cytokine and chemokine concentration in the serum and nasal drip (IL-33, sCD40L, VEGF, TNF-b,TNF-a, TGF-a, RANTES, PDGF-AB/BB, PDGF-AA, MIP-1b, MIP-1a MDC (CCL22), MCP-3, MCP-1, IP-10, IL-17A, IL-15, IL-13, IL-12 (p70), IL-12 (p40), IL-10, IL-9, IL-8, IL-7, IL-6, IL-5, IL-4, IL-3, IL-2, IL-1ra, IL-1b, IL-1a, IFN-g,IFN-a2, GRO, GM-CSF, G-CSF, Fractalkine, Flt-3 ligand, FGF-2, Eotaxin, EGF, GCP2, NAP2, MIP-3b, MIP-3a /CCL20, MIG, M-CSF, Lymphotactin, IL-29, IL-11, I-TAC, HCC-1, 6Ckine, TSLP, TRAIL, TPO, TARC, SDF-1A+b SCF, MIP-1d, MCP-4, MCP-2, LIF, IL-33, IL-28A, IL-23, IL-21, IL-20, IL-16, I-309, Eotaxin-3, Eotaxin-2, ENA-78, CTACK, BCA-1) (8)Age at the onset of asthma: only patients with asthma (9)Severity: only patients with asthma (10)Peripheral eosinophil counts: within a year before/after the blood sampling (11)Types of Viral infection (12)Medical treatment receiving at the enrollment (13)Inhaled corticosteroid use |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000022387 |